[18F]FDG PET/CT-based response assessment of stage IV non-small cell lung cancer treated with paclitaxel-carboplatin-bevacizumab with or without nitroglycerin patches
Purpose Nitroglycerin (NTG) is a vasodilating drug, which increases tumor blood flow and consequently decreases hypoxia. Therefore, changes in [18F] fluorodeoxyglucose positron emission tomography ([18F]FDG PET) uptake pattern may occur. In this analysis, we investigated the feasibility of [18F]FDG...
Gespeichert in:
| Veröffentlicht in: | European journal of nuclear medicine and molecular imaging 2017-01, Vol.44 (1), p.8-16 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 16 |
|---|---|
| container_issue | 1 |
| container_start_page | 8 |
| container_title | European journal of nuclear medicine and molecular imaging |
| container_volume | 44 |
| creator | de Jong, Evelyn E. C. van Elmpt, Wouter Leijenaar, Ralph T. H. Hoekstra, Otto S. Groen, Harry J. M. Smit, Egbert F. Boellaard, Ronald van der Noort, Vincent Troost, Esther G. C. Lambin, Philippe Dingemans, Anne-Marie C. |
| description | Purpose
Nitroglycerin (NTG) is a vasodilating drug, which increases tumor blood flow and consequently decreases hypoxia. Therefore, changes in [18F] fluorodeoxyglucose positron emission tomography ([18F]FDG PET) uptake pattern may occur. In this analysis, we investigated the feasibility of [18F]FDG PET for response assessment to paclitaxel-carboplatin-bevacizumab (PCB) treatment with and without NTG patches. And we compared the [18F]FDG PET response assessment to RECIST response assessment and survival.
Methods
A total of 223 stage IV non-small cell lung cancer (NSCLC) patients were included in a phase II study (NCT01171170) randomizing between PCB treatment with or without NTG patches. For 60 participating patients, a baseline and a second [18F]FDG PET/computed tomography (CT) scan, performed between day 22 and 24 after the start of treatment, were available. Tumor response was defined as a 30 % decrease in CT and PET parameters, and was compared to RECIST response at week 6. The predictive value of these assessments for progression free survival (PFS) and overall survival (OS) was assessed with and without NTG.
Results
A 30 % decrease in SUVpeak assessment identified more patients as responders compared to a 30 % decrease in CT diameter assessment (73 % vs. 18 %), however, this was not correlated to OS (SUVpeak30
p
= 0.833; CTdiameter30
p
= 0.557). Changes in PET parameters between the baseline and the second scan were not significantly different for the NTG group compared to the control group (
p
value range 0.159–0.634). The CT-based (part of the [18F]FDG PET/CT) parameters showed a significant difference between the baseline and the second scan for the NTG group compared to the control group (CT diameter decrease of 7 ± 23 % vs. 19 ± 14 %,
p
= 0.016, respectively).
Conclusions
The decrease in tumoral FDG uptake in advanced NSCLC patients treated with chemotherapy with and without NTG did not differ between both treatment arms. Early PET-based response assessment showed more tumor responders than CT-based response assessment (part of the [18F]FDG PET/CT); this was not correlated to survival. This might be due to timing of the [18F]FDG PET shortly after the bevacizumab infusion. |
| doi_str_mv | 10.1007/s00259-016-3498-y |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5121177</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1843911219</sourcerecordid><originalsourceid>FETCH-LOGICAL-c503t-c34e39fcdc40e87ddc542889fb246f89919dbddf59311a0fba1d16198c472f583</originalsourceid><addsrcrecordid>eNqNks9qFTEUhwdRbK0-gBsJuHETm2T-JRtBbntroaCLqxuRkMlk5qbMJNecTPX6QD6nmU69VEFwkxPId74kh1-WPafkNSWkPgVCWCkwoRXOC8Hx_kF2TCsqcE24eHjY1-QoewJwTQjljIvH2RGrq9TKyXH28zPl6y_rswv04XxzutrgRoFpUTCw8w4MUgAGYDQuIt8hiKo36PITct5hGNUwIG3SMkyuR1o5bQKKwaiYFN9s3KKd0oON6rsZsFah8btBRetwY26Utj-mUTUL58Nt9VNEzsbg-2GfXNYlQdRbA0-zR50awDy7qyfZx_X5ZvUOX72_uFy9vcK6JHnEOi9MLjrd6oIYXretLgvGuegaVlQdF4KKtmnbrhQ5pYp0jaLtPCSui5p1Jc9PsjeLdzc1o2l1-ndQg9wFO6qwl15Z-eeJs1vZ-xtZUkZpXSfBqztB8F8nA1GOFuYZKWf8BJLyktSc5qT6D7TIBU1ekdCXf6HXfgouTWKmGGdVdUvRhdLBAwTTHd5NiZwDI5fAyBQYOQdG7lPPi_sfPnT8TkgC2AJAOnK9Cfeu_qf1F2roz2M</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1842826619</pqid></control><display><type>article</type><title>[18F]FDG PET/CT-based response assessment of stage IV non-small cell lung cancer treated with paclitaxel-carboplatin-bevacizumab with or without nitroglycerin patches</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><creator>de Jong, Evelyn E. C. ; van Elmpt, Wouter ; Leijenaar, Ralph T. H. ; Hoekstra, Otto S. ; Groen, Harry J. M. ; Smit, Egbert F. ; Boellaard, Ronald ; van der Noort, Vincent ; Troost, Esther G. C. ; Lambin, Philippe ; Dingemans, Anne-Marie C.</creator><creatorcontrib>de Jong, Evelyn E. C. ; van Elmpt, Wouter ; Leijenaar, Ralph T. H. ; Hoekstra, Otto S. ; Groen, Harry J. M. ; Smit, Egbert F. ; Boellaard, Ronald ; van der Noort, Vincent ; Troost, Esther G. C. ; Lambin, Philippe ; Dingemans, Anne-Marie C.</creatorcontrib><description>Purpose
Nitroglycerin (NTG) is a vasodilating drug, which increases tumor blood flow and consequently decreases hypoxia. Therefore, changes in [18F] fluorodeoxyglucose positron emission tomography ([18F]FDG PET) uptake pattern may occur. In this analysis, we investigated the feasibility of [18F]FDG PET for response assessment to paclitaxel-carboplatin-bevacizumab (PCB) treatment with and without NTG patches. And we compared the [18F]FDG PET response assessment to RECIST response assessment and survival.
Methods
A total of 223 stage IV non-small cell lung cancer (NSCLC) patients were included in a phase II study (NCT01171170) randomizing between PCB treatment with or without NTG patches. For 60 participating patients, a baseline and a second [18F]FDG PET/computed tomography (CT) scan, performed between day 22 and 24 after the start of treatment, were available. Tumor response was defined as a 30 % decrease in CT and PET parameters, and was compared to RECIST response at week 6. The predictive value of these assessments for progression free survival (PFS) and overall survival (OS) was assessed with and without NTG.
Results
A 30 % decrease in SUVpeak assessment identified more patients as responders compared to a 30 % decrease in CT diameter assessment (73 % vs. 18 %), however, this was not correlated to OS (SUVpeak30
p
= 0.833; CTdiameter30
p
= 0.557). Changes in PET parameters between the baseline and the second scan were not significantly different for the NTG group compared to the control group (
p
value range 0.159–0.634). The CT-based (part of the [18F]FDG PET/CT) parameters showed a significant difference between the baseline and the second scan for the NTG group compared to the control group (CT diameter decrease of 7 ± 23 % vs. 19 ± 14 %,
p
= 0.016, respectively).
Conclusions
The decrease in tumoral FDG uptake in advanced NSCLC patients treated with chemotherapy with and without NTG did not differ between both treatment arms. Early PET-based response assessment showed more tumor responders than CT-based response assessment (part of the [18F]FDG PET/CT); this was not correlated to survival. This might be due to timing of the [18F]FDG PET shortly after the bevacizumab infusion.</description><identifier>ISSN: 1619-7070</identifier><identifier>EISSN: 1619-7089</identifier><identifier>DOI: 10.1007/s00259-016-3498-y</identifier><identifier>PMID: 27600280</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject><![CDATA[Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols - administration & dosage ; Bevacizumab - administration & dosage ; Carboplatin - administration & dosage ; Carcinoma, Non-Small-Cell Lung - diagnostic imaging ; Carcinoma, Non-Small-Cell Lung - drug therapy ; Carcinoma, Non-Small-Cell Lung - pathology ; Cardiology ; Feasibility Studies ; Female ; Fluorodeoxyglucose F18 ; Humans ; Imaging ; Lung cancer ; Lung Neoplasms - diagnostic imaging ; Lung Neoplasms - drug therapy ; Lung Neoplasms - pathology ; Male ; Medical imaging ; Medicine ; Medicine & Public Health ; Middle Aged ; Neoplasm Staging ; Netherlands ; Nitroglycerin - administration & dosage ; Nuclear Medicine ; Oncology ; Original ; Original Article ; Orthopedics ; Paclitaxel - administration & dosage ; Pharmacology ; Positron Emission Tomography Computed Tomography - methods ; Radiology ; Radiopharmaceuticals ; Reproducibility of Results ; Sensitivity and Specificity ; Survival Rate ; Tomography ; Treatment Outcome ; Vasodilator Agents - administration & dosage]]></subject><ispartof>European journal of nuclear medicine and molecular imaging, 2017-01, Vol.44 (1), p.8-16</ispartof><rights>The Author(s) 2016</rights><rights>European Journal of Nuclear Medicine and Molecular Imaging is a copyright of Springer, 2017.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c503t-c34e39fcdc40e87ddc542889fb246f89919dbddf59311a0fba1d16198c472f583</citedby><cites>FETCH-LOGICAL-c503t-c34e39fcdc40e87ddc542889fb246f89919dbddf59311a0fba1d16198c472f583</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00259-016-3498-y$$EPDF$$P50$$Gspringer$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00259-016-3498-y$$EHTML$$P50$$Gspringer$$Hfree_for_read</linktohtml><link.rule.ids>230,314,776,780,881,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27600280$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>de Jong, Evelyn E. C.</creatorcontrib><creatorcontrib>van Elmpt, Wouter</creatorcontrib><creatorcontrib>Leijenaar, Ralph T. H.</creatorcontrib><creatorcontrib>Hoekstra, Otto S.</creatorcontrib><creatorcontrib>Groen, Harry J. M.</creatorcontrib><creatorcontrib>Smit, Egbert F.</creatorcontrib><creatorcontrib>Boellaard, Ronald</creatorcontrib><creatorcontrib>van der Noort, Vincent</creatorcontrib><creatorcontrib>Troost, Esther G. C.</creatorcontrib><creatorcontrib>Lambin, Philippe</creatorcontrib><creatorcontrib>Dingemans, Anne-Marie C.</creatorcontrib><title>[18F]FDG PET/CT-based response assessment of stage IV non-small cell lung cancer treated with paclitaxel-carboplatin-bevacizumab with or without nitroglycerin patches</title><title>European journal of nuclear medicine and molecular imaging</title><addtitle>Eur J Nucl Med Mol Imaging</addtitle><addtitle>Eur J Nucl Med Mol Imaging</addtitle><description>Purpose
Nitroglycerin (NTG) is a vasodilating drug, which increases tumor blood flow and consequently decreases hypoxia. Therefore, changes in [18F] fluorodeoxyglucose positron emission tomography ([18F]FDG PET) uptake pattern may occur. In this analysis, we investigated the feasibility of [18F]FDG PET for response assessment to paclitaxel-carboplatin-bevacizumab (PCB) treatment with and without NTG patches. And we compared the [18F]FDG PET response assessment to RECIST response assessment and survival.
Methods
A total of 223 stage IV non-small cell lung cancer (NSCLC) patients were included in a phase II study (NCT01171170) randomizing between PCB treatment with or without NTG patches. For 60 participating patients, a baseline and a second [18F]FDG PET/computed tomography (CT) scan, performed between day 22 and 24 after the start of treatment, were available. Tumor response was defined as a 30 % decrease in CT and PET parameters, and was compared to RECIST response at week 6. The predictive value of these assessments for progression free survival (PFS) and overall survival (OS) was assessed with and without NTG.
Results
A 30 % decrease in SUVpeak assessment identified more patients as responders compared to a 30 % decrease in CT diameter assessment (73 % vs. 18 %), however, this was not correlated to OS (SUVpeak30
p
= 0.833; CTdiameter30
p
= 0.557). Changes in PET parameters between the baseline and the second scan were not significantly different for the NTG group compared to the control group (
p
value range 0.159–0.634). The CT-based (part of the [18F]FDG PET/CT) parameters showed a significant difference between the baseline and the second scan for the NTG group compared to the control group (CT diameter decrease of 7 ± 23 % vs. 19 ± 14 %,
p
= 0.016, respectively).
Conclusions
The decrease in tumoral FDG uptake in advanced NSCLC patients treated with chemotherapy with and without NTG did not differ between both treatment arms. Early PET-based response assessment showed more tumor responders than CT-based response assessment (part of the [18F]FDG PET/CT); this was not correlated to survival. This might be due to timing of the [18F]FDG PET shortly after the bevacizumab infusion.</description><subject>Adult</subject><subject>Aged</subject><subject>Antineoplastic Combined Chemotherapy Protocols - administration & dosage</subject><subject>Bevacizumab - administration & dosage</subject><subject>Carboplatin - administration & dosage</subject><subject>Carcinoma, Non-Small-Cell Lung - diagnostic imaging</subject><subject>Carcinoma, Non-Small-Cell Lung - drug therapy</subject><subject>Carcinoma, Non-Small-Cell Lung - pathology</subject><subject>Cardiology</subject><subject>Feasibility Studies</subject><subject>Female</subject><subject>Fluorodeoxyglucose F18</subject><subject>Humans</subject><subject>Imaging</subject><subject>Lung cancer</subject><subject>Lung Neoplasms - diagnostic imaging</subject><subject>Lung Neoplasms - drug therapy</subject><subject>Lung Neoplasms - pathology</subject><subject>Male</subject><subject>Medical imaging</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Neoplasm Staging</subject><subject>Netherlands</subject><subject>Nitroglycerin - administration & dosage</subject><subject>Nuclear Medicine</subject><subject>Oncology</subject><subject>Original</subject><subject>Original Article</subject><subject>Orthopedics</subject><subject>Paclitaxel - administration & dosage</subject><subject>Pharmacology</subject><subject>Positron Emission Tomography Computed Tomography - methods</subject><subject>Radiology</subject><subject>Radiopharmaceuticals</subject><subject>Reproducibility of Results</subject><subject>Sensitivity and Specificity</subject><subject>Survival Rate</subject><subject>Tomography</subject><subject>Treatment Outcome</subject><subject>Vasodilator Agents - administration & dosage</subject><issn>1619-7070</issn><issn>1619-7089</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNqNks9qFTEUhwdRbK0-gBsJuHETm2T-JRtBbntroaCLqxuRkMlk5qbMJNecTPX6QD6nmU69VEFwkxPId74kh1-WPafkNSWkPgVCWCkwoRXOC8Hx_kF2TCsqcE24eHjY1-QoewJwTQjljIvH2RGrq9TKyXH28zPl6y_rswv04XxzutrgRoFpUTCw8w4MUgAGYDQuIt8hiKo36PITct5hGNUwIG3SMkyuR1o5bQKKwaiYFN9s3KKd0oON6rsZsFah8btBRetwY26Utj-mUTUL58Nt9VNEzsbg-2GfXNYlQdRbA0-zR50awDy7qyfZx_X5ZvUOX72_uFy9vcK6JHnEOi9MLjrd6oIYXretLgvGuegaVlQdF4KKtmnbrhQ5pYp0jaLtPCSui5p1Jc9PsjeLdzc1o2l1-ndQg9wFO6qwl15Z-eeJs1vZ-xtZUkZpXSfBqztB8F8nA1GOFuYZKWf8BJLyktSc5qT6D7TIBU1ekdCXf6HXfgouTWKmGGdVdUvRhdLBAwTTHd5NiZwDI5fAyBQYOQdG7lPPi_sfPnT8TkgC2AJAOnK9Cfeu_qf1F2roz2M</recordid><startdate>20170101</startdate><enddate>20170101</enddate><creator>de Jong, Evelyn E. C.</creator><creator>van Elmpt, Wouter</creator><creator>Leijenaar, Ralph T. H.</creator><creator>Hoekstra, Otto S.</creator><creator>Groen, Harry J. M.</creator><creator>Smit, Egbert F.</creator><creator>Boellaard, Ronald</creator><creator>van der Noort, Vincent</creator><creator>Troost, Esther G. C.</creator><creator>Lambin, Philippe</creator><creator>Dingemans, Anne-Marie C.</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>7QO</scope><scope>8FD</scope><scope>FR3</scope><scope>P64</scope><scope>5PM</scope></search><sort><creationdate>20170101</creationdate><title>[18F]FDG PET/CT-based response assessment of stage IV non-small cell lung cancer treated with paclitaxel-carboplatin-bevacizumab with or without nitroglycerin patches</title><author>de Jong, Evelyn E. C. ; van Elmpt, Wouter ; Leijenaar, Ralph T. H. ; Hoekstra, Otto S. ; Groen, Harry J. M. ; Smit, Egbert F. ; Boellaard, Ronald ; van der Noort, Vincent ; Troost, Esther G. C. ; Lambin, Philippe ; Dingemans, Anne-Marie C.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c503t-c34e39fcdc40e87ddc542889fb246f89919dbddf59311a0fba1d16198c472f583</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Antineoplastic Combined Chemotherapy Protocols - administration & dosage</topic><topic>Bevacizumab - administration & dosage</topic><topic>Carboplatin - administration & dosage</topic><topic>Carcinoma, Non-Small-Cell Lung - diagnostic imaging</topic><topic>Carcinoma, Non-Small-Cell Lung - drug therapy</topic><topic>Carcinoma, Non-Small-Cell Lung - pathology</topic><topic>Cardiology</topic><topic>Feasibility Studies</topic><topic>Female</topic><topic>Fluorodeoxyglucose F18</topic><topic>Humans</topic><topic>Imaging</topic><topic>Lung cancer</topic><topic>Lung Neoplasms - diagnostic imaging</topic><topic>Lung Neoplasms - drug therapy</topic><topic>Lung Neoplasms - pathology</topic><topic>Male</topic><topic>Medical imaging</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Neoplasm Staging</topic><topic>Netherlands</topic><topic>Nitroglycerin - administration & dosage</topic><topic>Nuclear Medicine</topic><topic>Oncology</topic><topic>Original</topic><topic>Original Article</topic><topic>Orthopedics</topic><topic>Paclitaxel - administration & dosage</topic><topic>Pharmacology</topic><topic>Positron Emission Tomography Computed Tomography - methods</topic><topic>Radiology</topic><topic>Radiopharmaceuticals</topic><topic>Reproducibility of Results</topic><topic>Sensitivity and Specificity</topic><topic>Survival Rate</topic><topic>Tomography</topic><topic>Treatment Outcome</topic><topic>Vasodilator Agents - administration & dosage</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>de Jong, Evelyn E. C.</creatorcontrib><creatorcontrib>van Elmpt, Wouter</creatorcontrib><creatorcontrib>Leijenaar, Ralph T. H.</creatorcontrib><creatorcontrib>Hoekstra, Otto S.</creatorcontrib><creatorcontrib>Groen, Harry J. M.</creatorcontrib><creatorcontrib>Smit, Egbert F.</creatorcontrib><creatorcontrib>Boellaard, Ronald</creatorcontrib><creatorcontrib>van der Noort, Vincent</creatorcontrib><creatorcontrib>Troost, Esther G. C.</creatorcontrib><creatorcontrib>Lambin, Philippe</creatorcontrib><creatorcontrib>Dingemans, Anne-Marie C.</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>Biotechnology Research Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>European journal of nuclear medicine and molecular imaging</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>de Jong, Evelyn E. C.</au><au>van Elmpt, Wouter</au><au>Leijenaar, Ralph T. H.</au><au>Hoekstra, Otto S.</au><au>Groen, Harry J. M.</au><au>Smit, Egbert F.</au><au>Boellaard, Ronald</au><au>van der Noort, Vincent</au><au>Troost, Esther G. C.</au><au>Lambin, Philippe</au><au>Dingemans, Anne-Marie C.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>[18F]FDG PET/CT-based response assessment of stage IV non-small cell lung cancer treated with paclitaxel-carboplatin-bevacizumab with or without nitroglycerin patches</atitle><jtitle>European journal of nuclear medicine and molecular imaging</jtitle><stitle>Eur J Nucl Med Mol Imaging</stitle><addtitle>Eur J Nucl Med Mol Imaging</addtitle><date>2017-01-01</date><risdate>2017</risdate><volume>44</volume><issue>1</issue><spage>8</spage><epage>16</epage><pages>8-16</pages><issn>1619-7070</issn><eissn>1619-7089</eissn><abstract>Purpose
Nitroglycerin (NTG) is a vasodilating drug, which increases tumor blood flow and consequently decreases hypoxia. Therefore, changes in [18F] fluorodeoxyglucose positron emission tomography ([18F]FDG PET) uptake pattern may occur. In this analysis, we investigated the feasibility of [18F]FDG PET for response assessment to paclitaxel-carboplatin-bevacizumab (PCB) treatment with and without NTG patches. And we compared the [18F]FDG PET response assessment to RECIST response assessment and survival.
Methods
A total of 223 stage IV non-small cell lung cancer (NSCLC) patients were included in a phase II study (NCT01171170) randomizing between PCB treatment with or without NTG patches. For 60 participating patients, a baseline and a second [18F]FDG PET/computed tomography (CT) scan, performed between day 22 and 24 after the start of treatment, were available. Tumor response was defined as a 30 % decrease in CT and PET parameters, and was compared to RECIST response at week 6. The predictive value of these assessments for progression free survival (PFS) and overall survival (OS) was assessed with and without NTG.
Results
A 30 % decrease in SUVpeak assessment identified more patients as responders compared to a 30 % decrease in CT diameter assessment (73 % vs. 18 %), however, this was not correlated to OS (SUVpeak30
p
= 0.833; CTdiameter30
p
= 0.557). Changes in PET parameters between the baseline and the second scan were not significantly different for the NTG group compared to the control group (
p
value range 0.159–0.634). The CT-based (part of the [18F]FDG PET/CT) parameters showed a significant difference between the baseline and the second scan for the NTG group compared to the control group (CT diameter decrease of 7 ± 23 % vs. 19 ± 14 %,
p
= 0.016, respectively).
Conclusions
The decrease in tumoral FDG uptake in advanced NSCLC patients treated with chemotherapy with and without NTG did not differ between both treatment arms. Early PET-based response assessment showed more tumor responders than CT-based response assessment (part of the [18F]FDG PET/CT); this was not correlated to survival. This might be due to timing of the [18F]FDG PET shortly after the bevacizumab infusion.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>27600280</pmid><doi>10.1007/s00259-016-3498-y</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1619-7070 |
| ispartof | European journal of nuclear medicine and molecular imaging, 2017-01, Vol.44 (1), p.8-16 |
| issn | 1619-7070 1619-7089 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5121177 |
| source | MEDLINE; Springer Nature - Complete Springer Journals |
| subjects | Adult Aged Antineoplastic Combined Chemotherapy Protocols - administration & dosage Bevacizumab - administration & dosage Carboplatin - administration & dosage Carcinoma, Non-Small-Cell Lung - diagnostic imaging Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - pathology Cardiology Feasibility Studies Female Fluorodeoxyglucose F18 Humans Imaging Lung cancer Lung Neoplasms - diagnostic imaging Lung Neoplasms - drug therapy Lung Neoplasms - pathology Male Medical imaging Medicine Medicine & Public Health Middle Aged Neoplasm Staging Netherlands Nitroglycerin - administration & dosage Nuclear Medicine Oncology Original Original Article Orthopedics Paclitaxel - administration & dosage Pharmacology Positron Emission Tomography Computed Tomography - methods Radiology Radiopharmaceuticals Reproducibility of Results Sensitivity and Specificity Survival Rate Tomography Treatment Outcome Vasodilator Agents - administration & dosage |
| title | [18F]FDG PET/CT-based response assessment of stage IV non-small cell lung cancer treated with paclitaxel-carboplatin-bevacizumab with or without nitroglycerin patches |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T04%3A16%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=%5B18F%5DFDG%20PET/CT-based%20response%20assessment%20of%20stage%20IV%20non-small%20cell%20lung%20cancer%20treated%20with%20paclitaxel-carboplatin-bevacizumab%20with%20or%20without%20nitroglycerin%20patches&rft.jtitle=European%20journal%20of%20nuclear%20medicine%20and%20molecular%20imaging&rft.au=de%20Jong,%20Evelyn%20E.%20C.&rft.date=2017-01-01&rft.volume=44&rft.issue=1&rft.spage=8&rft.epage=16&rft.pages=8-16&rft.issn=1619-7070&rft.eissn=1619-7089&rft_id=info:doi/10.1007/s00259-016-3498-y&rft_dat=%3Cproquest_pubme%3E1843911219%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1842826619&rft_id=info:pmid/27600280&rfr_iscdi=true |